Trial Profile
A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant/Intolerant Meniere's Disease (CR-MD) and Corticosteroid-Resistant/Intolerant Autoimmune Inner Ear Disease Disease (CR-AIED)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Autoimmune disorders; Ear disorders; Meniere's disease
- Focus Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 14 Feb 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 18 Oct 2022 Planned End Date changed from 1 Sep 2022 to 31 Dec 2024.